Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant Suicidality Analysis Should Include “Activation” Symptoms

Executive Summary

FDA should expand its analysis of pediatric antidepressant data to include examination of "activation" symptoms, a joint FDA advisory committee told the agency Feb. 2

You may also be interested in...



FDA Requests Antidepressant Labeling Add Suicidality Warning

FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior

FDA Requests Antidepressant Labeling Add Suicidality Warning

FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior

Antidepressant Labeling Should Reflect Negative Pediatric Studies

Antidepressant labeling should be revised to reflect negative efficacy data for pediatric patients, a joint FDA advisory committee suggested Feb. 2

Related Content

UsernamePublicRestriction

Register

PS043326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel